Ursodeoxycholic Acid Powder (128-13-2) Specifications
Product Name | Ursodeoxycholic acid |
Chemical Name | (R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid |
Synonym | UDCA;
Ursodiol; Tauroursodiol;Urosodeoxycholic Acid; Ursodeoxycholic acid(micronized); URSODEOXYCHOLIC ACID; URSODESOXYCHOLIC ACID; URSODEOXYCHOLOC ACID; |
CAS Number | 128-13-2 |
InChIKey | RUDATBOHQWOJDD-UZVSRGJWSA-N |
Molecular Formula | C24H40O4 |
Molecular Weight | 392.57 |
Monoisotopic Mass | 392.29265975 |
Melting Point | 203-204 °C (lit.) |
Boiling Point | 437.26°C (rough estimate) |
Density | 0.9985 (rough estimate) |
Color | White – almost white |
Solubility | ethanol: 50 mg/mL, clear |
Storage Temperature | 2-8°C |
Application | Ursodeoxycholic acid (UDCS) is a cell protectant used extensively to mitigate hepatic and biliary diseases. Ursodeoxycholic acid may be used to study its specific activities that range from reduction of cholesterol absorpition, cholesterol gallstone dissolution to suppression of immune response. |
Testing Report | Available |
Ursodeoxycholic acid (UDCA), also known as Ursodiol, is a bile acid secreted into the bile juice. It was first discovered in the bile of bears. Although it is not the major bile acid in humans, it has been found to have significant therapeutic properties. The history of UDCA use in humans can be traced to ancient times in China.
Currently, exogenous UDCA is used globally to treat and manage various hepatobiliary conditions, like gallstone diseases (cholelithiasis), primary biliary cholangitis, and primary sclerosing cholangitis.
Why do you need to take ursodeoxycholic acid (ursodiol)?
Ursodeoxycholic acid (ursodiol) helps protect hepatocytes and cholangiocytes and prevents any further damage to them. UDCA powder has also been shown to improve the overall survival of patients in various hepatobiliary conditions.
What is Ursodeoxycholic Acid(UDCA) Powder?
As mentioned above, Ursodeoxycholic acid powder is a synthetic form of UDCA used to treat patients suffering from various hepatobiliary conditions. Ursodeoxycholic acid powder has been found to be effective in Primary Biliary Cirrhosis and has been shown to improve the survival of patients. To find the best Ursodeoxycholic acid powder and get good price, you maybe need to buy Ursodeoxycholic acid powder wholesale.
Physicochemical Properties of Ursodeoxycholic Acid
UDCA (3α, 7β-dihydroxy5β-cholanoic acid) is a secondary bile acid. It is formed after the enzymatic action of intestinal microorganisms on primary bile acids. Primary bile acids are in turn, formed from the enzymatic hydroxylation reaction of cholesterol.
UDCA powder has been shown to have hepato-protective properties. Usually, the majority of primary and secondary bile acids produced are hydrophobic. On the other hand, Ursodeoxycholic acid powderis hydrophilic and decreases the oxidative damage caused by hydrophobic acids. The hydrophilic property of Ursodeoxycholic acid powder is the basis for oral UDCA therapy, which is convenient and easy.
After taking exogenous UDCA orally, absorption occurs primarily in the small intestine by passive non-ionic diffusion. UDCA is then broken down in the proximal jejunum while it mixes with micelles of endogenous bile acids. After its uptake into the liver, conjugation of UDCA takes place. UDCA is then conjugated with glycine and to a lesser degree with taurine. It is then actively secreted into the bile via enterohepatic circulation.
Ursodeoxycholic acid conjugates thus formed are absorbed mainly from the distal ileum. Nonabsorbed UDCA passes into the colon and is converted by intestinal bacteria to lithocholic acid. Lithopolis acid is mostly insoluble and excreted in faeces. A small fraction of lithocholic acid is absorbed. It is then sulfated in the liver, secreted into the bile, and finally excreted in the feces.
Ursodeoxycholic Acid/Ursodiol Powder Mechanism of Action
Ursodeoxycholic acid powder has shown to have multiple mechanisms of action, and there are still mechanisms that are under study.
Ursodeoxycholic acid powder has shown to be significantly useful in protecting cholangiocyte injury against toxic effects of bile acids, stimulation of biliary secretion which is impaired previously, stimulation in the detoxification process against hydrophobic bile acids, or inhibition of apoptosis, i.e., self-medicated cell death of hepatocytes.
It is still not well understood which of these mechanisms is responsible primarily for the beneficial effects of UDCA. Besides, the degree of benefit from UDCA also depends on the individual’s specific condition and the disease stage.
What Are the Main Sources of Ursodeoxycholic acid powder On the Market?
Although humans produce UDCA, it is significantly lower than other bile acids produced. Therefore, an alternative search is still ongoing. To date, ursodeoxycholic acid powder production in bears has been in significant amounts.
Since there are animal rights implications and a poaching risk, alternative sources are being looked upon. Among them, bovine UDCA powder has shown good results. Other sources like yeast and algae are also being looked upon. Synthetic production of UDCA from precursor molecules is also of significant interest. However, the cost implications are also being considered. The latest development in the area is looking at plant sources as an alternative. There are many synthetic ursodeoxycholic acid powder for sale, find the true source of ursodeoxycholic acid powder supplier, ou need to pay more attention to it. And ursodeoxycholic acid supplements are available on line.
The Benefits & Effects of Ursodeoxycholic Acid Powder
What are the ursodeoxycholic acid benefits ? UDCA powder has shown significant improvement and is limited to various hepatobiliary conditions. It is used to treat and manage various hepatobiliary conditions, like gallstone diseases (cholelithiasis), primary biliary cholangitis, and primary sclerosing cholangitis.
It has been shown to positively impact immune regulation, lowering cholesterol, dissolving gallbladder stones, protecting the liver, and lowering blood lipids levels to name a few. Although the exact mechanism by which UDCA does so is still an area of research, the known mechanisms have already been discussed above.
What is Ursodeoxycholic acid powder Used for?
Ursodeoxycholic acid (ursodiol) is used majorly and extensively for various liver and bile ducts pathology. However, its use is not limited just to hepatobiliary conditions per se. Through years of vigorous research, UDCA’s positive impact on treating various conditions has been proven. This includes dissolving gallbladder stones and preventing and treating cholesterol gallstones. UDCA powder is also used as an anionic detergent for biochemical research, an anti-cholelithiasis agent, an anticonvulsant, and a cytoprotective agent. Other uses of ursodeoxycholic acid powder are still an area of interest in various ongoing research and clinical trials.
How to Take Ursodeoxycholic Acid Powder?
Ursodeoxycholic acid supplement is usually not sold over the counter and, most of the time requires a doctor’s prescription. Before using UDCA, it is important to discuss the potential risk vs. benefit with your doctor. The doctor will often discuss on the lines of medical history, particularly hepatobiliary diseases and allergic history. Even though UDCA is used for hepatobiliary diseases, there are some hepatobiliary diseases where caution needs to be applied.
Therefore, an extensive discussion with the doctor is of paramount importance and more so if you have some past medical history along the line of ascites (fluid accumulation in the peritoneal cavity), bleeding varices (veins that enlarge and bleed), hepatic encephalopathy (brain pathology due to liver failure), liver damage in the past, liver transplantation, biliary tract outflow obstruction, biliary tract problems, and pancreatitis.
When all the discussions show no significant risks, UDCA is usually prescribed as follows:
For gallstone disease:
Adults and children 12 years of age and older—The ursodeoxycholic acid dosage is usually 8 to 10 milligrams (mg) per kilogram (kg) of body weight per day, divided into two or three doses.
Children younger than 12 years of age—This is generally determined by the doctor.
For primary biliary cirrhosis:
Adults—The dosage is usually 13 to 15 milligrams (mg) per kilogram (kg) of body weight per day, divided into two to four doses. Your doctor may adjust your dose as needed.
Children— This is generally determined by the doctor
For prevention of gallstones during rapid weight loss:
Adults—The ursodeoxycholic acid dosage is usually 300 milligrams (mg) two times a day.
Children younger than 12 years of age— This is generally determined by the doctor.
Most of the time, if a single dose is missed, taking the missed dose as soon as possible is advised if the time from the last dose was no longer than 4 hours. In multiple missed doses, a consultation with the doctor is necessary.
UDCA has to be taken adhering to the doctor’s prescription. In case of an overdose, it is highly unlikely that a single extra dose will cause harm. However, in case of a significant overdose, it is best to contact your doctor or visit the nearest hospital.
Like every medication, there is always a side effect to a degree. It is best to contact your doctor or nearest hospital if any of the following ursodeoxycholic acid side effects are seen:
Common symptoms
Bladder pain, bloody or cloudy urine, burning or painful urination, dizziness, fast heartbeat, frequent urge to urinate, indigestion, lower back or side pain, severe nausea, skin rash or itching over the entire body, stomach pain, vomiting, weakness.
Less common symptoms
Black and tarry stools, chest pain, chills or fever, cough, pinpoint red spots on the skin, severe or continuing stomach pain, sore throat or swollen glands, sores or ulcers or white spots on the lips or in the mouth, unusual bleeding or bruising, unusual tiredness or weakness.
The general relief of symptoms has been shown to appear within 3-6 weeks of starting the treatment with UDCA powder. The duration of the course of therapy varies from individual to individual. The prescribing doctor assesses the situation from time to time. Therefore, timely follow-ups are essential. Ursodeoxycholic acid powder has been found safe in individuals who have continuously taken it for up to 6 months and even in individuals who have taken it for 48 months. It is, therefore, safe to say that UDCA powder is safe for long-term usage, provided there is timely follow-up and regular liver function tests are done timely.
What Is the Best Medicine for Liver Diseases?
There is no absolute best remedy or a single shot regime for all liver diseases. Ursodeoxycholic acid powder, however, is useful and not limited to the various hepatobiliary conditions, like gallstone diseases (cholelithiasis), primary biliary cholangitis, and primary sclerosing cholangitis.
Can I Take Ursodiol/Ursodeoxycholic Acid with Other Medications?
UDCA is relatively a safe drug. However, caution needs to be applied if any other medications containing cholestyramine, colestimide, colestipol, aluminum hydroxide, and smectite are being taken along with UDCA because the absorption UDCA is impaired by them. Metabolic drug interactions with compounds metabolized by cytochrome P4503A are seen along with other drugs like ciclosporin, nitrendipine, and dapsone.
Is Ursodeoxycholic Acid Powder Good for the Liver?
Ursodeoxycholic Acid Powder is overall good for the liver because of its protective actions on cholangiocytes and hepatocytes, protection against injury from toxic effects of bile acids, stimulation of biliary secretion, and stimulation in the detoxification process against hydrophobic bile acids and inhibition of apoptosis, i.e., self-medicated cell death of hepatocytes.
UDCA or Udiliv(commercial name) has also been used to manage the fatty liver disease, especially Non-alcoholic steatohepatitis(NASH), with significantly good outcomes. However, further research and meta-analyses are necessary for absolute validity.
What Are the Differences Between Ursodeoxycholic Acid(UDCA) And Chenodeoxycholic Acid(CDCA)?
UDCA and CDCA both are bile acids. In humans, both UDCA and Chenodeoxycholic Acid(CDCA) are produced. However, CDCA is produced in significantly larger amounts. Both UDCA and CDCA are breakdown products of cholesterol, to begin with. CDCA is a primary bile acid, i.e., it is mainly synthesized by the liver from cholesterol, whereas UDCA is produced as a result of enzymatic breakdown by bacteria in the gut.
As such, in the context of gallstone disease, Ursodeoxycholic Acid(UDCA) was significantly more efficacious than was CDCA in both lower and higher dose regimes.
Buy Ursodeoxycholic Acid powder bulk? | Where to find best Ursodeoxycholic Acid powder manufacturer?
Ursodeoxycholic acid powder bulk can be bought online through various websites. However, you need to be careful regarding the authenticity and quality of the product. A detailed check of the active ingredients and concentration must be done first. Phcoker is the best ursodeoxycholic acid powder manufacturer.
Ursodeoxycholic Acid: The Ultimate FAQ Guide
Does ursodiol really work?
Yes. Ursodiol has shown to be effective in treating various hepatobiliary conditions, provided there is an early diagnosis, and the treatment is started as early as possible.
What medication dissolves gallbladder sludge?
UDCA powder has been proven to be effective in dissolving gallbladder sludge.
Can ursodiol cause weight gain?
UDCA powder can cause weight gain, particularly in the first 12 months of treatment.
ls ursodiol a steroid?
Steroids are categorical of different types. Both steroids and bile acids are synthesized or are metabolic products of cholesterol. Some studies have shown the steroid-like nature of bile acids in regulating daily body functions. However, more research in the field is needed for conclusive evidence.
Is ursodiol an immunosuppressant?
UDCA has been found to have some immunosuppressant properties.
Does ursodiol lower bile acids?
UDCA has shown to be effective in stimulating detoxification against hydrophobic acids. Ursodeoxycholic acid powder has also been shown to reduce hydrophobic acids. However, further research is still necessary.
Does ursodiol improve liver enzymes?
UDCA has been proven effective in improving liver enzymes in various liver pathologies.
Is ursodeoxycholic acid powder good for the kidney?
Research conducted on rats showed no harm by UDCA powder. However, extensive research on humans is still ongoing.
Can ursodiol help fatty liver?
UDCA is beneficial in fatty liver. However, carefully designed trials are still underway for the same topic.
Does ursodiol lower triglycerides?
UDCA has been found to lower Low-density lipoproteins (LDL) and Very Low-Density Lipoproteins (VLDL). However, the total triglyceride level has no significant changes following treatment with UDCA powder.
Is there an alternative to ursodiol?
There is an alternative treatment to UDCA. However, the effectiveness and efficacy of those agents have been a debate. Consulting the doctor regarding the approach and what is best for you would be helpful.
ls ursocol an antibiotic?
No, ursocol is not an antibiotic. It is a drug with various functions but primarily protects the hepatocytes and helps in the breakdown of gallstones.
Is cholestasis a liver disease?
Cholestasis simply means that the bile stops flowing along the biliary tree or the flow is slow. This obstruction in the flow of bile can cause liver injury and disease.
How effective is ursodeoxycholic acid?
UDCA is effective in the treatment of various hepatobiliary diseases as well as other conditions.
What kind of drug is ursodiol?
UDCA is a secondary bile acid. It is significantly useful in protecting cholangiocyte injury against toxic effects of bile acids, stimulation of biliary secretion which is impaired previously, stimulation in the detoxification process against hydrophobic bile acids, or inhibition of apoptosis i.e., self-medicated cell death of hepatocytes.
Does ursodiol lower cholesterol?
Studies show that Ursodeoxycholic acid powder can reduce cholesterol levels.
Can ursodiol cause pancreatitis?
Pancreatitis with UDCA use is not common. UDCA has been used for the treatment of pancreatitis.
Does ursodiol make you sleepy?
Tiredness and weakness are amongst the least common side effects of UDCA.
References
- Use of ursodeoxycholic acid in liver diseases. D Kumar, R K Tandon.J Gastroenterol Hepatol. 2001 Jan;16(1):3-14. doi: 10.1046/j.1440-1746.2001.02376.x.PMID: 11206313
- Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.Gustav Paumgartner , Ulrich Beuers.PMID: 12198643 DOI: 10.1053/jhep.2002.36088 Hepatology. 2002 Sep;36(3):525-31.
- Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.Gustav Paumgartner, Ulrich Beuers.PMID: 15062194 DOI: 10.1016/S1089-3261(03)00135-1 Clin Liver Dis. 2004 Feb;8(1):67-81, vi.
- Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart.Noorul Izzati Hanafi, Anis Syamimi Mohamed, Siti Hamimah Sheikh Abdul Kadir, Mohd Hafiz Dzarfan Othman.PMID: 30486474 PMCID: PMC6316857 DOI: 10.3390/biom8040159 Biomolecules. 2018 Nov 27;8(4):159.
- Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.Binu V John, Nidah S Khakoo, Kaley B Schwartz, Gabriella Aitchenson, Cynthia Levy, Bassam Dahman, Yangyang Deng, David S Goldberg, Paul Martin, David E Kaplan, Tamar H Taddei.PMID: 33989225 PMCID: PMC8410631 (available on 2022-09-01) DOI: 10.14309/ajg.0000000000001280 Am J Gastroenterol. 2021 Sep 1;116(9):1913-1923.
- What is the influence of long-term ursodeoxycholic acid therapy in patients with primary biliary cirrhosis?Virginia C Clark, Cynthia Levy.PMID: 17290236 DOI: 10.1038/ncpgasthep0741 Nat Clin Pract Gastroenterol Hepatol. 2007 Apr;4(4):188-9.
- Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review. Fabio Tonin and Isabel W C E Arendscorresponding author.PMCID: PMC5827811 PMID: 29520309 doi: 10.3762/bjoc.14.33 Beilstein J Org Chem. 2018; 14: 470–483.
- Bear bile: dilemma of traditional medicinal use and animal protection. Yibin Feng,corresponding author Kayu Siu,Ning Wang,Kwan-Ming Ng, Sai-Wah Tsao, Tadashi Nagamatsu, and Yao Tong.PMCID: PMC2630947 PMID: 19138420 doi: 10.1186/1746-4269-5-2 J Ethnobiol Ethnomed. 2009; 5: 2.
- Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones.G S Tint, G Salen, A Colalillo, D Graber, D Verga, J Speck, S Shefer.PMID: 7051912 doi: 10.7326/0003-4819-97-3-351. Ann Intern Med. 1982 Sep;97(3):351-6.
- Gallstone dissolution therapy with ursodiol. Efficacy and safety. G Salen.PMID: 2689115 DOI: 10.1007/BF01536661 Dig Dis Sci. 1989 Dec;34(12 Suppl):39S-43S.
- Ursodeoxycholic acid — adverse effects and drug interactions. Hempfling,K. Dilger,U. Beuers
- Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial.Keith D. Lindor,Kris V. Kowdley,E. Jenny Heathcote,M. Edwyn Harrison,Roberta Jorgensen,Paul Angulo,James F. Lymp,Lawrence Burgart,Patrick Colin
- High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial†.Ulrich F. H. Leuschner,Birgit Lindenthal,Günter Herrmann,Joachim C. Arnold,Martin Rössle,Hans-Jörg Cordes,Stefan Zeuzem,Jasper Hein,Thomas Berg,the NASH Study Group
- Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial.Keith D. Lindor,Kris V. Kowdley,E. Jenny Heathcote,M. Edwyn Harrison,Roberta Jorgensen,Paul Angulo,James F. Lymp,Lawrence Burgart,Patrick Colin
- The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.Zun Xiang, Yi-peng Chen, Kui-fen Ma, Yue-fang Ye, Lin Zheng, Yi-da Yang, You-ming Li, Xi Jin.PMID: 24053454 PMCID: PMC3848865 DOI: 10.1186/1471-230X-13-140 BMC Gastroenterol. 2013 Sep 23;13:140.
- Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study.E Roda, F Bazzoli, A M Labate, G Mazzella, A Roda, C Sama, D Festi, R Aldini, F Taroni, L Barbara.PMID: 7141392 DOI: 10.1002/hep.1840020611 Hepatology. Nov-Dec 1982;2(6):804-10.